Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 in Hypertrophic Scars
NCT05196373Phase 2Withdrawn
- Sponsor
- Sirnaomics
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of sirna-tgf-b1 + sirna-cox-2 in Hypertrophic Scar (HS), sponsored by Sirnaomics. Planned start Dec 2021; status: withdrawn.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT05196373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196373.